In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of ...
So the stock is attached to a real, maturing franchise. The question is what the mRNA platform is worth, and the honest ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Pharmaceutical Technology on MSN
CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug
The pair will work together to progress lixudebart across multiple rare kidney and liver diseases.
Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 1 / 12 Episodes Total]IntroductionLigand Pharmaceuticals ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie and Alkermes . AbbVie (ABBV) In a report released yesterday, Vamil Divan fr ...
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Join Us at the Blue Hope Bash to Support the Fight Against Colorectal Cancer / Blue Hope Bash Committee, cancer, colorectal ...
Guggenheimanalyst Vamil Divan maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and maintains the target price at ...
Quince Therapeutics, Inc. announced that Effective as of October 8, 2026, John Militello, CPA, was appointed as Chief Financial Officer of the Company. John Militello, CPA, age 53, has served as Head ...
Accordingto Bank of America Securities' initial coverage report, AP301's revenue in the Chinese market could reach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results